In addition, flecainide prevented exercise-induced ventricular arrhythmias in two patients carrying a CPVT-linked RyR mutation who were refectory to conventional therapy (Watanabe et al., 2009). The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.